Please login to the form below

Not currently logged in
Email:
Password:

EASD: Study supports early use of Victoza

Novo Nordisk's GLP-1 analogue Victoza has greater benefit ifused early in the treatment of type 2 diabetes according to a study presentedat the European Association for the Study of Diabetes meeting

Novo Nordisk's GLP-1 analogue Victoza (liraglutide) has greater benefit if used early in the treatment of type 2 diabetes according to a study presented at the European Association for the Study of Diabetes (EASD) meeting in Lisbon, Portugal.

When used early in the treatment process, 72 per cent of patients treated with Victoza were able to achieve glycaemic control compared to 49 per cent who were treated late on. Glycaemic control was defined as the EASD target of HbA1c levels of less than 7 per cent.

Both results were significantly higher than compared to comparator groups in the trial: patients who had not received treatment before or previously only one oral anti-diabetic drug.

A separate study also presented at EASD showed that patients who switched from oral therapy with sitagliptin (marketed as Januvia by Merck) to once-daily injectable therapy with Victoza had an increase in overall treatment satisfaction based on the Diabetes Treatment Satisfaction Questionnaire at 52 and 78 weeks.

Study investigator, Professor Eduard Montanya from the Medical School of the University of Barcelona, Spain, said the increased satisfaction was partly due to greater weight loss associated with Victoza.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics